Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Beta Bionics Inc (BBNX)

Beta Bionics Inc (BBNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Beta Bionics Updates Commercialization Timeline Expectations for Mint™, its Patch Pump in Development GlobeNewswire - Thu May 21, 3:04PM CDT

IRVINE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it expects to...

BBNX : 11.82 (+11.40%)
MarketBeat.com
Beta Bionics Touts Pharmacy Push, iLet Momentum and 2027 Mint Patch Pump Plans MarketBeat - Wed May 13, 1:05AM CDT

Beta Bionics (NASDAQ:BBNX) Chief Financial Officer Stephen Feider said the company’s first-quarter outperformance was supported by increasing use of the pharmacy reimbursement channel, expanded sales...

BBNX : 11.82 (+11.40%)
Beta Bionics to Present at the Bank of America Securities Health Care Conference GlobeNewswire - Mon Apr 27, 3:25PM CDT

IRVINE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management...

BBNX : 11.82 (+11.40%)
Beta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance GlobeNewswire - Tue Apr 21, 3:03PM CDT

IRVINE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results...

BBNX : 11.82 (+11.40%)
Beta Bionics: The FDA Remediation Deadline Arrives as Growth Momentum Gets Its First Real Test Barchart - Mon Apr 20, 4:01PM CDT

Barchart Research What to Expect from BBNX Earnings BBNX Generated April 20, 2026 Current Price $12.91 EPS Estimate $$-0.53 Consensus Rating Moderate Buy Average Move 13.49% Beta Bionics: The FDA Remediation...

BBNX : 11.82 (+11.40%)
Beta Bionics Introduces Bionic Insights™ in Bionic Reports — Transforming How Clinicians Understand and Optimize Diabetes Care GlobeNewswire - Tue Mar 31, 5:00AM CDT

IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Beta Bionics today announced the launch of  Bionic Insights™ , an innovative new feature within its Bionic Reports, designed to help healthcare providers...

BBNX : 11.82 (+11.40%)
Beta Bionics to Announce First Quarter 2026 Financial Results on April 21, 2026 GlobeNewswire - Mon Mar 30, 3:11PM CDT

IRVINE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to...

BBNX : 11.82 (+11.40%)
BBNX SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics PR Newswire - Sat Mar 28, 9:25AM CDT

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their...

BBNX : 11.82 (+11.40%)
SHAREHOLDER INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Continues Investigation of Potential Securities Claims Against Bionics (NASDAQ: BBNX) PR Newswire - Tue Mar 17, 1:00PM CDT

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their Options...

BBNX : 11.82 (+11.40%)
INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics PR Newswire - Thu Mar 12, 8:23AM CDT

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their Options...

BBNX : 11.82 (+11.40%)

Barchart Exclusives

Qualcomm Stock Is the Sleeping Giant of the AI Revolution. It’s Starting to Wake Up. Barchart - Sun May 24, 4:41PM CDT
Long weighed down by smartphone market stagnation and the impending loss of Apple as a client, Qualcomm is staging a powerful comeback as it transitions to an aggressive offensive in AI data center inference and physical AI. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.